John M. Lachin, Trevor J. Orchard, and David M. Nathan, for the DCCT/EDIC Research Group. Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 2014;37:39–43. doi: 10.2337/dc13-2116 Grâce à l’étude DCCT (Diabetes Control and Complications Trial), il est désormais établi […]
Lloyd DJ et al. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors., Nature 2013, 504 : 437- 440. doi: 10.1038/nature12724 La glucokinase (GK) est une enzyme clé de la régulation de l’homéostasie glucidique, qui convertit le glucose en glucose-6-phosphate (G6P), première étape de la glycolyse. La GK se comporte dans les cellules ß […]
Tobias DK, Pan A, Jackson CL, O’Reilly EJ, Ding EL, Willett WC, Manson JE, Hu FB. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014 Jan 16;370(3):233-44. doi: 10.1056/NEJMoa1304501 Un excès de masse grasse est un facteur de risque de décès précoce lié aux maladies cardiovasculaires […]
Hidalgo B et al. Epigenome-Wide Association Study of Fasting Measures of Glucose, Insulin, and HOMA-IR in the Genetics of Lipid Lowering Drugs and Diet Network Study, Diabetes 2014;63(2):801- 7. doi: 10.2337/db13-1100 L’étude des traits métaboliques intermédiaires du diabète de type 2 (DT2) a permis d’identifier chez des individus non diabétiques de nouveaux marqueurs […]
Zhao W, Katzmarzyk P, Horswell R, Wang Y, Johnson J, Hu G. HbA1c and Coronary Heart Disease risk Among Diabetic Patients. Diabetes Care 2014;37:428–435. doi: 10.2337/dc13-1525 Si les études épidémiologiques ont mis en évidence un lien entre amélioration de l’équilibre glycémique et réduction du risque cardio-vasculaire [1,2], cette association reste plus discutée dans […]
Laitinen OH et al. Coxsackievirus B1 is associated with induction of ß-cell autoimmunity that portends type 1 diabetes. Diabetes 2014, 63 : 446-455. doi: 10.2337/db13-0619 L’augmentation rapide de l’incidence du diabète de type 1 (DT1) sur les trente dernières années suggère fortement l’implication de facteurs environnementaux dans la physiopathologie de la maladie. Les […]
Flannick et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes, Nature Genetics, Mar, 2014. doi: 10.1038/ng.2915 Les études pangénomiques ont identifié plus de 65 loci associés au risque de diabète de type 2 (DT2), ce qui a permis de mettre en évidence de nouvelles voies métaboliques impliquées dans le développement de […]
Antenatal lifestyle advice for women who are overweight or obese: LIMIT randomised trial Jodie M Dodd, Deborah Turnbull, Andrew J McPhee, Andrea R Deussen, Rosalie M Grivel, Lisa N Yelland, Caroline A Crowther. Gary Wittert, Julie A Owens, Jeffrey S Robinson. doi: 10.1136/bmj.g1285 Aux Etats Unis, la moitié des femmes enceintes débutent la […]
Preiss D. et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol 2014;2:116–24. doi: 10.1016/S2213-8587(13)70152-9 Les sujets non diabétiques présentant une anomalie de la glycémie à jeun ont un risque cardiovasculaire augmenté [1], ce qui fait suggérer que l’insulinorésistance est un facteur de […]
Rigby MR et al. Targeting of memory cells with alefacept in new-onset type 1 diabetes (T1DAL study) : 12 month results of a randomised, double blind placebo-controlled phase 2 trial. Lancet Diabetes Endocrinology 2013, 1 : 284-294. doi: 10.1016/S2213-8587(13)70111-6 Un des objectifs des essais thérapeutiques au diagnostic de diabète de type 1 (DT1) […]
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
